Biospecimen Processing and Storage Core
生物样本处理和存储核心
基本信息
- 批准号:10289497
- 负责人:
- 金额:$ 18.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-20 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:Acute Lymphocytic LeukemiaAcute Myelocytic LeukemiaAcute leukemiaAdolescentAdultAliquotApplications GrantsBiological FactorsBiologyBloodBlood specimenBone MarrowBone Marrow CellsCancer CenterCatalogsCellsCerebrospinal FluidChildChildhood Acute Lymphocytic LeukemiaClinicalClinical TrialsCodeCollectionComprehensive Cancer CenterCore FacilityDNADataDatabasesDevelopmentDoctor of PhilosophyEnsureEthnic groupFreezingFrequenciesFutureGeneticGoalsGrantHealthHepatotoxicityHodgkin DiseaseInformation StorageLatinoLeukocytesLiquid substanceLocationMalignant NeoplasmsMedicineMethotrexateMononuclearPatientsPediatric Oncology GroupPediatricsPeripheral Blood Mononuclear CellPilot ProjectsPlasmaPopulation SciencesPostdoctoral FellowProceduresProcessResearchResearch Project GrantsResearch SupportResourcesSamplingServicesShippingShipsSiteSpecimenTexasTherapeuticTimeTissuesTranslational ResearchTreatment-related toxicityTumor BiologyVulnerable Populationsbiobankcancer health disparitycancer preventioncentral databasecollegeethnic disparityexperienceexperimental studyhealth disparityimproved outcomeinsightleukemia/lymphomamembermid-career facultyneurotoxicityperipheral bloodprofessorprogramsracial and ethnicrecruitsample collectionsocial health determinantstenure tracktranslational research programtranslational study
项目摘要
PROJECT SUMMARY Biospecimen Processing and Storage Core (Core B)
The proposed cancer health disparities translational research program in this P20 planning grant
application relies on the submission of serial peripheral blood, bone marrow and cerebrospinal fluid (CSF)
specimens from children and adolescents with acute lymphoblastic leukemia (ALL) across the
participating clinical recruitment sites of the Reducing Ethnic Disparities in Acute Leukemia (REDIAL)
Consortium. The Biospecimen Processing and Storage Core (BPSC) will serve as the central location
where these samples will be processed into the materials needed for the specific studies in Research
Projects 1 (treatment-associated hepatotoxicity) and 2 (methotrexate neurotoxicity), as well as
determination of genetic ancestry for use across all projects, and biobanking of material that will be
available for pilot projects through the Developmental Research Program (DRP). This Core will support
the collection, shipping, processing, and storage of patient samples from each study site, as well as
provide up-to-date and accurate sample annotation. The Core will follow previously developed standard
operating procedures to ensure uniform collection and processing for optimal sample yield and quality.
The Aims of the Core are to: 1) Receive and catalog blood, bone marrow and CSF provided by the
Consortium sites; 2) Process all patient samples to isolate plasma, peripheral blood mononuclear cells,
and bone marrow mononuclear cells, and separate blasts from non-blasts where appropriate; 3) Allocate
and distribute samples to Projects; and 4) Maintain a biobank of samples for future research. The resulting
biobank will become an extremely valuable resource for this and future translational studies examining
ethnic disparities in childhood ALL.
项目摘要生物测量处理和存储核心(核心B)
拟议的癌症健康差异转化研究计划中的P20计划赠款
应用依赖于提交系列外周血,骨髓和脑脊液(CSF)
来自儿童和青少年患有急性淋巴细胞白血病(全部)的标本
参与急性白血病种族差异的临床招聘部位(REDIAIL)
财团。生物循环处理和存储核心(BPSC)将作为中心位置
这些样品将被处理成研究的特定研究所需的材料
项目1(与治疗相关的肝毒性)和2(甲氨蝶呤神经毒性)以及
确定遗传祖先用于在所有项目中使用,以及材料的生物群
通过发展研究计划(DRP)可用于试点项目。这个核心将支持
每个研究站点的患者样品的收集,运输,处理和存储以及
提供最新和准确的样品注释。核心将遵循先前开发的标准
操作程序以确保收集和处理统一,以获得最佳的样本收率和质量。
核心的目的是:1)接收和分类血液,骨髓和CSF由
财团地点; 2)处理所有患者样品以分离血浆,外周血单核细胞,
和骨髓单核细胞,并在适当的情况下将爆炸与非爆炸分开; 3)分配
并将样本分发给项目; 4)维护样本的生物库,以供将来研究。结果
生物库将成为研究和将来的翻译研究的极其宝贵的资源
童年时代的种族差异。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Terzah M Horton其他文献
Terzah M Horton的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Terzah M Horton', 18)}}的其他基金
Identifying Cell Stress Proteins that Predict Clinical Response in Pediatric AML
鉴定可预测儿童 AML 临床反应的细胞应激蛋白
- 批准号:
8439807 - 财政年份:2013
- 资助金额:
$ 18.71万 - 项目类别:
Identifying Cell Stress Proteins that Predict Clinical Response in Pediatric AML
鉴定可预测儿童 AML 临床反应的细胞应激蛋白
- 批准号:
8613472 - 财政年份:2013
- 资助金额:
$ 18.71万 - 项目类别:
Identifying Cell Stress Proteins that Predict Clinical Response in Pediatric AML
鉴定可预测儿童 AML 临床反应的细胞应激蛋白
- 批准号:
8838738 - 财政年份:2013
- 资助金额:
$ 18.71万 - 项目类别:
Proteosome Inhibition Therapy for Hematologic Malignancy
血液恶性肿瘤的蛋白酶体抑制疗法
- 批准号:
7623964 - 财政年份:2006
- 资助金额:
$ 18.71万 - 项目类别:
Proteosome Inhibition Therapy for Hematologic Malignancy
血液恶性肿瘤的蛋白酶体抑制疗法
- 批准号:
7840394 - 财政年份:2006
- 资助金额:
$ 18.71万 - 项目类别:
Proteosome Inhibition Therapy for Hematologic Malignancy
血液恶性肿瘤的蛋白酶体抑制疗法
- 批准号:
7418956 - 财政年份:2006
- 资助金额:
$ 18.71万 - 项目类别:
Proteosome Inhibition Therapy for Hematologic Malignancy
血液恶性肿瘤的蛋白酶体抑制疗法
- 批准号:
7030593 - 财政年份:2006
- 资助金额:
$ 18.71万 - 项目类别:
MITOCHONDRIAL DNA MUTATIONS IN CARCINOGENESIS
致癌过程中的线粒体 DNA 突变
- 批准号:
3034782 - 财政年份:1993
- 资助金额:
$ 18.71万 - 项目类别:
相似海外基金
Targeting Menin in Acute Leukemia with Upregulated HOX Genes
通过上调 HOX 基因靶向急性白血病中的 Menin
- 批准号:
10655162 - 财政年份:2023
- 资助金额:
$ 18.71万 - 项目类别:
Alternatively spliced cell surface proteins as drivers of leukemogenesis and targets for immunotherapy
选择性剪接的细胞表面蛋白作为白血病发生的驱动因素和免疫治疗的靶点
- 批准号:
10648346 - 财政年份:2023
- 资助金额:
$ 18.71万 - 项目类别:
Preclinical Validation of Personalized Molecular Assays for Measurable Residual Disease Monitoring in Pediatric AML
用于儿科 AML 可测量残留疾病监测的个性化分子检测的临床前验证
- 批准号:
10643568 - 财政年份:2023
- 资助金额:
$ 18.71万 - 项目类别:
Clonal analysis of cancer by mitochondrial DNA barcoding
通过线粒体 DNA 条形码对癌症进行克隆分析
- 批准号:
10612155 - 财政年份:2023
- 资助金额:
$ 18.71万 - 项目类别: